Production (Stage)
Adaptimmune Therapeutics plc
ADAP
$0.2801
$0.00572.08%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -47.58M | -74.22M | -17.62M | 69.52M | -48.50M |
| Total Depreciation and Amortization | 2.47M | 2.84M | 2.82M | 2.74M | 2.83M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -125.00K | 11.63M | 5.88M | 2.49M | 3.37M |
| Change in Net Operating Assets | -21.35M | 25.55M | -45.53M | -27.35M | 10.36M |
| Cash from Operations | -66.59M | -34.20M | -54.45M | 47.40M | -31.95M |
| Capital Expenditure | -1.20M | -219.00K | -143.00K | -422.00K | -102.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 42.36M | 8.39M | -65.88M | -321.00K | -256.00K |
| Cash from Investing | 41.15M | 8.17M | -66.02M | -743.00K | -358.00K |
| Total Debt Issued | -- | 0.00 | 25.00M | 24.50M | -- |
| Total Debt Repaid | -25.45M | -- | -- | -- | -- |
| Issuance of Common Stock | 131.00K | 1.00K | 1.00K | 12.00K | 29.24M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -25.32M | 1.00K | 25.00M | 24.51M | 29.24M |
| Foreign Exchange rate Adjustments | 556.00K | -180.00K | 214.00K | -20.00K | -416.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -50.20M | -26.22M | -95.25M | 71.15M | -3.49M |